Episode
Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
- Podcast
- Business Of Biotech
- Published
- Jul 20, 2026
- Duration seconds
- 3387
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/late-stage-development-and-commercial-planning-with-cervomed-s-matt-winton-ph-d/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/late-stage-development-and-commercial-planning-with-cervomed-s-matt-winton-ph-d.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in dementia with Lewy bodies (DLB) and commercial planning for an anticipated launch. Winton talks about CMC and manufacturing scale-up, partnership, communicating with regulators and the benefits of global regulatory alignment on protocols for the P...